Sutro Biopharma (STRO)
(Delayed Data from NSDQ)
$3.77 USD
-0.15 (-3.83%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $3.78 +0.01 (0.27%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
STRO 3.77 -0.15(-3.83%)
Will STRO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for STRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for STRO
Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates
STRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
XOMA Royalty (XOMA) Reports Q2 Loss, Tops Revenue Estimates
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Lags Revenue Estimates
Spruce Biosciences, Inc. (SPRB) Reports Q1 Loss, Tops Revenue Estimates
Other News for STRO
Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
World?s First AutoStore? Installation Handling Frozen Goods Installed by StrongPoint
Analyst Expectations For Sutro Biopharma's Future
STRO Crosses Below Key Moving Average Level
TD Cowen Sticks to Its Buy Rating for Sutro Biopharma (STRO)